ONCS has more than doubled in stock price with the advancement of three Phase 2 trials.
Look ahead I think ONCS could triple this year once MCC data begins to roll out. If data is positive and strong uptake of IL-12 is verified, the FDA might green-light an accelerated approval, breakthrough designation, and almost certainly an orphan indication. If so, and with $200-$300 million in peak sales from this indication, ONCS could become a $500 million company over the next 24 months; this would be upside of more than 500%.
At $0.47, a $2.80 price target may sound too bullish, but in biotechnology we see moves like this all the time.
MCC might be ONCS' most promising short-term indication.
wise4stocks, I completely agree. Also, furbush87 is right by saying MCC is not priced into the stock. Everyone knows that ONCS will have to complete another trial for MCC because the endpoints used likely would not satisfy the FDA. However, depending on the results, that trial could be small and set for accelerated approval. An accelerated approval or breakthrough designation (no current treatments or ongoing trials) would completely change the outlook and valuation of this company. It could be huge.
we should get MCC data at the same time as Melanoma final data. ONCS has previously stated that Melanoma is their primary focus for now so I don't think any MCC is priced in currently. You are correct an orphan drug status could do us wonders that won't come till 60 days after data is released. So I see a double from here till June when data should be released, might get another 20-50% from there on orphan drug, however with a dillution most likely late this year along with Phase 3 not starting till Dec or Jan 15 I'm not sure a tripple is likely. Not that anyone should complain with "only" doubling their money